New article in Pediatric Research provides roadmap for critically needed COVID-19 research in children

May 15, 2020

FOR IMMEDIATE RELEASE Contact: Berna Diehl Phone: 202-725-2553 Email: berna@brightoncomms.com   Article by I-ACT for Children, other leading pediatric researchers stresses urgency in addressing the questions surrounding children and the disease   Rockville, MD– Increasing reports of severe COVID-19 illness in children – coupled with the fact that little is known about how and why…

I-ACT for Children Launches Emergency Access Program to Speed Pediatric Clinical Trials for COVID-19

May 14, 2020

FOR IMMEDIATE RELEASE Contact: Berna Diehl Phone: 202-725-2553 Email: berna@brightoncomms.com Emergency program will allow any company developing COVID-19 treatments or vaccines to tap into pediatric global network, trial-planning experts Rockville, MD, – As the number of children with severe COVID-19 illness grows, there is increasing urgency to ensure that potential treatments and vaccines are tested for…

I-ACT for Children Welcomes Gary Noel, MD, as Chief Medical Officer

November 12, 2019

The Institute for Advanced Clinical Trials (I-ACT) for Children is pleased to announce the appointment of Gary Noel, MD, as its Chief Medical Officer. Dr. Noel is a pediatrician, child advocate, specialist in Infectious Diseases and Immunology and a seasoned expert in drug development, having spent more than 30 years in leadership roles in the…

I-ACT FOR CHILDREN TO CO-HOST DUCHENNE MUSCULAR DYSTROPHY PLATFORM TRIAL STAKEHOLDER MEETING

September 3, 2019

SHERATON SILVER SPRING | SILVER SPRING, MD SEPTEMBER 9, 2019 | 8:30 AM-4:30 PM I-ACT for Children will co-host the first Duchenne Muscular Dystrophy Platform Trial Community Meeting on Sept. 9 with collaborators Parent Project Muscular Dystrophy and the Critical Path Institute. The Duchenne Platform Trial is being designed to increase access to therapeutic trials…

I-ACT for Children Selects Advarra as Central IRB for its Pediatric Clinical Trials Site Network

June 10, 2019

I-ACT for Children has selected Advarra as the central IRB for the I-ACT for Children Clinical Trials Site Network – a geographically and therapeutically diverse network of pediatric trial sites committed to improving efficiencies and capabilities for the conduct of clinical trials. I-ACT for Children launched the central IRB function to streamline processes, expedite IRB…

Chiesi Group Joins I-ACT for Children as an Annual Member

April 24, 2019

Today I-ACT for Children welcomes Chiesi Group as our newest Annual Member. Click on the link below for more details. Full press release

Bayer Joins I-ACT for Children as an Annual Member

April 15, 2019

We are thrilled to welcome Bayer AG as I-ACT for Children’s newest Annual Member! Click on the image below to read the full announcement.

Eli Lilly and Company Joins I-ACT for Children as a Sustaining Member

March 19, 2019

We are delighted to announce that Eli Lilly and Company has joined I-ACT for Children as our newest Sustaining Member. Please click the image below for the press release and full details.

Dr. Rosenberg will Co-lead a Workshop at the International Meeting on Simulation in Healthcare

January 25, 2019

I-ACT for Children’s Dr. Carol Rosenberg (read full bio), Quality Improvement Project Manager, will co-lead a workshop at the International Meeting on Simulation in Healthcare (http://imsh2019.com/) on January 29th.  Dr. Rosenberg will co-lead a workshop with Drs. Jennifer Arnold and Maria Carmen Diaz that focuses on the use of high-fidelity simulators to educate patients and their family…

Novartis Joins I-ACT for Children as a Sustaining Member

October 12, 2018

We are thrilled to welcome Novartis as our newest sustaining member, click the image below to read the full press release.  

You can “ACT for Children” by donating to this effort today!

The Institute’s work relies on financial contributions from individuals, groups, institutions and others